See how Novartis is responding to Coronavirus (COVID-19)
This site is intended for UK healthcare professionals only. If you are a member of the public, please click here
Professor Caroline Robert (Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University) presents the latest 5-year data (pooled analysis) on the use of Tafinlar + Mekinist for the management of BRAF V600 metastatic melanoma.
Filmed June 2019.
The separate data from the COMBI-v and COMBI-d trials, on which this is based, can be viewed here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]
